#NCI-Funded Research to Prevent and Treat #HIV-Associated #Cancer
The widespread use of antiretroviral therapy to suppress the HIV virus has helped people with HIV live healthier, longer lives—but unfortunately, people living with HIV have an increased risk of cancer. For 25 years, the AIDS Malignancy Consortium (AMC) has led national and international efforts to prevent and treat HIV-related cancers.
Now, Montefiore Health System and Albert Einstein College of Medicine have received a five-year, $111 million grant from the National Cancer Institute (NCI) to lead this research consortium. Joseph Sparano, M.D., associate chair for clinical research in the department of oncology at Montefiore and associate director for clinical research at the NCI-designated Albert Einstein Cancer Center, is principal investigator (PI) on the grant.
Dr. Sparano explains why people living with HIV are at an increased risk for developing certain types of cancer and describes some of the major advances driven by AMC researchers, which ultimately benefit both those with many different types of cancer such as Non-Hodgkin lymphoma whether or not they have HIV. He also discusses the goals of the AMC including completion of the ANCHOR Study, the first ever clinical trial of its kind to focus on the prevention and treatment of anal cancer, which is caused by the human papilloma virus (HPV) by detecting and treating anal dysplasia.
Rebecca Levine, M.D. and Renee Huang, M.D. are the principal investigator and co-investigator, respectively, at the Montefiore-Einstein site of the ANCHOR Study, which stands for Anal Cancer HSIL Outcomes Research. Dr. Levine and Dr. Huang are surgical oncologists at Montefiore and assistant professors of surgery at Einstein.
#HIVcancer #AIDS #ANCHORStudy #HIVresearch #cancerresearch #NIH #HPV #AnalCancer #analdysplasia #HumanPapillomavirus #HSIL
-
Category
No comments found